ISEE — IVERIC bio Share Price
0.000.00%
Last trade - 00:00HealthcareAdventurousLarge Cap
- $5.51bn
- $5.01bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 11.55 | ||
| Price to Tang. Book | 11.55 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -39.91% | ||
| Return on Equity | -55.02% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 12.6 | 149.47 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
IVERIC bio, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of treatments for retinal diseases with unmet medical needs. Its lead asset is its clinical-stage product candidate, avacincaptad pegol, which is also referred to as ACP or Zimura, a complement C5 inhibitor. Zimura is targeting diseases including geographic atrophy (GA), intermediate age-related macular degeneration (AMD), and autosomal recessive Stargardt disease (STGD1). In addition to ACP, the Company is also developing its preclinical product candidate, IC-500, a high temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor for GA secondary to AMD and potentially other age-related retinal diseases. Its portfolio also includes several ongoing gene therapy research programs, each of which uses adeno-associated virus (AAV) for gene delivery. These AAV mediated gene therapy programs are targeting the orphan inherited retinal diseases (IRDs).
Directors
- Pravin Dugel PRE (57)
- Glenn Sblendorio CEO (65)
- David Carroll CFO (55)
- Keith Westby COO (46)
- Anthony Gibney EVP
- Christopher Simms SVP
- Adrienne Graves LED (67)
- Christine Miller DRC
- Mark Blumenkranz IND (68)
- Axel Bolte IND (49)
- Jane Henderson IND (56)
- Calvin Roberts IND (68)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- January 5th, 2007
- Public Since
- September 25th, 2013
- No. of Shareholders
- 96
- No. of Employees
- 74
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 137,976,851
- Address
- 8 SYLVAN WAY, Suite 2372, PARSIPPANY, 07054
- Web
- https://ivericbio.com/
- Phone
- +1 6094746755
- Auditors
- Ernst & Young LLP
Upcoming Events for ISEE
Q3 2023 IVERIC bio Inc Earnings Release
Similar to ISEE
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the IVERIC bio share price?
As of Today at 01:12 UTC, shares in IVERIC bio are trading at $39.95. This share price information is delayed by 15 minutes.
How has the IVERIC bio share price performed this year?
Shares in IVERIC bio last closed at $39.95 and the price had moved by +241.16% over the past 365 days. In terms of relative price strength the IVERIC bio share price has outperformed the S&P500 Index by +190.02% over the past year.
What are the analyst and broker recommendations for IVERIC bio?
The overall consensus recommendation for IVERIC bio is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the IVERIC bio dividend yield?
IVERIC bio does not currently pay a dividend.
Does IVERIC bio pay a dividend?
IVERIC bio does not currently pay a dividend.
When does IVERIC bio next pay dividends?
IVERIC bio does not currently pay a dividend.
How do I buy IVERIC bio shares?
To buy shares in IVERIC bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of IVERIC bio?
As of the previous close price of $39.95, shares in IVERIC bio had a market capitalisation of $5.51bn.
Where are IVERIC bio shares listed?
Here are the trading details for IVERIC bio:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ISEE
What kind of share is IVERIC bio?
Based on an overall assessment of its quality, value and momentum IVERIC bio is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a IVERIC bio share price forecast for 2023?
The analyst consensus target price for shares in IVERIC bio is $38.71. That is 3.1% below the last closing price of $39.95.
Analysts covering IVERIC bio currently have a consensus Earnings Per Share (EPS) forecast of -$1.86 for the next financial year.
What is the trend in the IVERIC bio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like IVERIC bio. Over the past six months, its share price has outperformed the S&P500 Index by +84.72%.
As of the last closing price of $39.95, shares in IVERIC bio were trading +53.11% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the IVERIC bio PE Ratio?
The IVERIC bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $39.95.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of IVERIC bio?
IVERIC bio's management team is headed by:
- Pravin Dugel - PRE
- Glenn Sblendorio - CEO
- David Carroll - CFO
- Keith Westby - COO
- Anthony Gibney - EVP
- Christopher Simms - SVP
- Adrienne Graves - LED
- Christine Miller - DRC
- Mark Blumenkranz - IND
- Axel Bolte - IND
- Jane Henderson - IND
- Calvin Roberts - IND